Molecular Bioprocessing as a New Paradigm for Drug Discovery

Originally delivered Mar 2, 2010
You will be able to download and print a certificate for these PDH credits once the content has been viewed. If you have already viewed this content, please click here to login.

The drug discovery process is expensive and often inefficient. With the emergence of genomic and proteomic information, the growth of critical molecular targets is rapid. Nevertheless, the development of active, selective, and safe drug candidates (small molecule or biopharmaceutical) has not kept pace with such advances. For small molecules, a core problem is the lack of high-throughput and accurate methodologies for ADME/Tox, which forces comprehensive toxicology studies to be performed only on later stage lead compounds and preclinical candidates. For biopharmaceuticals, the ability to accurately reproduce the human protein with correct posttranslational modification is limited by lack of knowledge of cellular machinery and then the efficient scale up of protein production and purification. Professor Dordick will detail his research in the design and optimization of high-throughput, microscale discovery and development platforms and the emergence of using bioprocessing strategies at early stages of drug discovery.

Presenter(s): 

Checkout

Checkout

Do you already own this?

Log In for instructions on accessing this content.

AIChE MEMBERS

AIChE Member Credits 1
AIChE Members $69.00
AIChE Undergraduate Student Members Free
AIChE Graduate Student Members Free
SBE Members Free
Non-Members** $99.00
Webinar content is available with the kind permission of the author(s) solely for the purpose of furthering AIChE’s mission to educate, inform and improve the practice of professional chemical engineering. All other uses are forbidden without the express consent of the author(s). For permission to re-use, please contact chemepermissions@aiche.org.
  • Type:
    Archived Webinar
  • Level:
    Advanced
  • PDHs:
    1.00

Share This Post: